Skip to main content

Table 1 Patient characteristics and previous therapy regimens

From: Low-dose peripheral blood stem cell graft after high-dose chemotherapy - an evaluation of hematopoietic reconstitution

Parameter

Overall cohort

Group1 (3–4 × 106 CD34+ cells/kg bw)

Group 2 (2–2.5 × 106 CD34+ cells /kg bw)

P value Group 1 vs. 2

Group 3 (< 2 × 106 CD34+ cells /kg bw)

Patient number, n

148

86

53

/

9

Sex, n (%)

   

0.030

 

 Male

87 (59)

44 (51)

37 (70)

6 (67)

 Female

61 (41)

42 (49)

16 (30)

3 (33)

Diagnosis of MM, n (%)

 Median age at first diagnosis, years (range)

60 (41–72)

60 (44–72)

61 (41–71)

0.854

60 (46–72)

 Stage at first diagnosis

   

/

 

  I

7 (5)

4 (5)

3 (6)

9 (100)

  II

4 (3)

3 (3)

1 (2)

0 (0)

  III

136 (92)

79 (92)

48 (91)

0 (0)

  NA

1 (1)

0 (0)

1 (2)

0 (0)

  A

129 (87)

78 (91)

44 (83)

/

7 (78)

  B

18 (12)

8 (9)

8 (15)

2 (22)

  NA

1 (1)

0 (0)

1 (2)

0 (0)

 Heavy chain type

   

0.767a

 

  IgG

95 (64)

56 (65)

37 (70)

2 (22)

  IgA

29 (20)

17 (20)

8 (15)

4 (44)

  IgD

1 (1)

1 (1)

0 (0)

0 (0)

  Light chain only

23 (16)

12 (14)

8 (15)

3 (33)

 Light chain type

   

0.452

 

  kappa

96 (65)

53 (62)

36 (68)

7 (78)

  lambda

52 (35)

33 (38)

17 (32)

2 (22)

Induction therapy, n (%)

 Median number of cycles (range)

4 (2–8)

4 (2–6)

4 (3–8)

 

4 (3–5)

  VCD

70 (47)

39 (45)

28 (53)

0.297b

3 (33)

  VRD

30 (20)

22 (26)

8 (15)

0 (0)

  Elotuzumab-VRd

33 (22)

22 (26)

10 (19)

1 (11)

  Other/modifications

15 (10)

3 (3)

7 (13)

5 (56)

Mobilization therapy, n (%)

   

/

 

 1xCAD

143 (97)

85 (99)

50 (94)

8 (89)

 Other

5 (3)

1 (1)

3 (6)

1 (11)

Remission prior PBSC collection, n (%)

 nCR

25 (17)

19 (22)

5 (9)

0.041c

1 (11)

 VGPR

52 (35)

34 (40)

17 (32)

1 (11)

 PR

54 (36)

25 (29)

25 (47)

4 (44)

 MR

8 (5)

5 (6)

2 (4)

1 (11)

 SD

1 (1)

1 (1)

0 (0)

0 (0)

 NA

8 (5)

2 (2)

4 (8)

 

2 (22)

  1. aIgD not included
  2. bOther/modifications not included
  3. cnCR/VGPR versus PR/MR/SD
  4. CAD cyclophosphamide, doxorubicin, dexamethasone; MM multiple myeloma; MR minimal response; NA not available; nCR near complete remission; PBSC peripheral blood stem cells; PR partial remission; SD stable disease; VCD bortezomib, VGPR very good partial remission; VRD(d) vincristine, lenalidomide (revlimid), dexamethasone; cyclophosphamide, dexamethasone; vs., versus